ANKRD30B

Across TCGA pan-cancer cohorts, ANKRD30B Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated ANKRD30B data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ANKRD30B Mutation is associated with better overall survival. In most high-consensus cancer types, elevated ANKRD30B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, STAD, and CESC are the cancer types where ANKRD30B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	0.973	0.856	.002	36	view →
STAD	DFS	Median	II,III,IV	0.154	0.643	<.001	24	view →
CESC	DFS	Median	III,IV	0.053	0.729	<.001	18	view →
SKCM	DFS	Median	III,IV	0.187	0.660	.002	15	view →
KIRP	OS	Median	All	0.270	0.904	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	12	view →
LGG	OS	Median	All	0.415	0.814	<.001	10	view →
SCLC	DFS	Median	II,III,IV	0.307	0.655	.005	9	view →
ACC	OS	Median	All	0.140	0.623	.002	9	view →
HNSC	OS	Median	IV	0.169	0.708	.011	6	view →
PRAD	DFS	Median	All	0.617	0.886	.029	6	view →
SARC	DFS	Median	All	0.198	0.612	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

ANKRD30B–UCEC (OS)

Open the UCEC breakdown →